Search clinical trials for: Etravirine

Total 115 results

University of Colorado, Denver
Gilead Sciences

Completed

Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance

Weight Gain | HIV-1-infection

United States
University of North Carolina, Chapel Hill
Merck Sharp & Dohme LLC

Recruiting

Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women

HIV Infections | Pregnancy Related

United States
IRCCS Eugenio Medea
University of Rome Tor Vergata

Completed

Safety and Efficacy of Etravirine in Friedreich Ataxia Patients (FAEST1)

Friedreich Ataxia

Italy
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)

HIV-1 Infection
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children

HIV Infections

United States, Brazil, South Africa
Gamaleya Research Institute of Epidemiology and...
MSD Pharmaceuticals LLC

Not yet recruiting

HIV A6 Genome In ART Unsuccessful Patients On DOR (HIV-A6-DOR)

Virus-HIV
Tibotec Pharmaceuticals, Ireland

Completed

TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients

HIV-Infections
University of Colorado, Denver

Completed

Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers

Hepatitis C | HIV

United States
Merck Sharp & Dohme LLC

Completed

A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)

Renal Impairment
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

HIV-1

United States, France, Spain, Portugal, Canada, United Kingdom, South Africa, Argentina, Brazil, Puerto Rico, Thailand, Netherlands, Romania
Merck Sharp & Dohme LLC

Completed

Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)

Human Immunodeficiency Virus-1 (HIV-1)
University of Southern California
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma

HIV

United States
GlaxoSmithKline

Completed

DDI Study of Etravirine and GSK1265744

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
University of Roma La Sapienza

Recruiting

Non-Interventional Observational Retrospective Study to Evaluate Doravirine Based-regimens in HIV Infected Aged Patients (DORAge). (DORAge)

HIV

Italy
Clinique du Quartier Latin
Merck Frosst Canada Ltd.

Unknown

HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance

HIV Infections

Canada, Martinique
Fundación FLS de Lucha Contra el Sida, las Enfermedades...
Merck Sharp & Dohme LLC

Completed

Removal of Doravirine by Hemodialysis in HIV-Infected Patients With End-stage Renal Disease (ESRD)

HIV-infected Participants With ESRD Undergoing Routine Hemodialysis

Spain
Chelsea and Westminster NHS Foundation Trust
Merck Sharp & Dohme LLC; Imperial College London; University of Liverpool

Completed

Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers

Human Immunodeficiency Virus

United Kingdom
Merck Sharp & Dohme LLC

Completed

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

HIV-1 Infection

United States, Chile, France, United Kingdom
Germans Trias i Pujol Hospital

Completed

Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression

HIV

Spain
Fundacion Clinic per a la Recerca Biomédica

Active, not recruiting

Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance

HIV-1-infection

Spain
ViiV Healthcare
Pfizer

Withdrawn

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Hepatitis B | Hepatitis C, Chronic | Human Immunodeficiency Virus

United States, Canada, Poland
Merck Sharp & Dohme LLC

Completed

A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)

HIV-1 Infection
Braintree Laboratories

Completed

A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children

Constipation

United States
Merck Sharp & Dohme LLC

Recruiting

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Human Immunodeficiency Virus (HIV) Infection

United States, Mexico, Russian Federation, South Africa, Thailand
Institut de Médecine et d'Epidémiologie Appliquée...
Merck Sharp & Dohme LLC

Active, not recruiting

"Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk" (DORASPEP)

HIV Infections

France
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Janssen-Cilag Ltd.

Completed

Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

HIV-1 Infection

Spain, France
University of North Carolina, Chapel Hill
Janssen Pharmaceuticals

Completed

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection

HIV Infections

United States
Janssen R&D Ireland

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients

Human Immunodeficiency Virus (HIV) Infection

France, Ukraine, United States, Mexico, Romania, South Africa, Peru, Argentina, Puerto Rico, Russian Federation, Guatemala
University Hospital, Geneva
University Hospital, Basel, Switzerland; University of Lausanne Hospitals; University... and other collaborators

Completed

Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz (SWITCH-EE)

Sleep Disorders

Switzerland
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP2-C197: A Phase I Trial to Investigate the Pharmacokinetic Interaction Between Lopinavir/Ritonavir and TMC125 Both at Steady-state in Healthy Volunteers.

HIV
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use

HIV Infection
Tibotec Pharmaceuticals, Ireland

Completed

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

Human Immunodeficiency Virus Type 1
Janssen Sciences Ireland UC

Active, not recruiting

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants

HIV Infections | HIV-1

United States, France, Spain, South Africa, Canada, Argentina, Thailand, Brazil, Romania, Panama, Puerto Rico
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.

Fungal Infection | HIV | AIDS
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial

HIV Infection
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients (SENSE)

Acquired Immunodeficiency Syndrome | HIV Infection | HIV

France, United Kingdom, Germany, Spain, Switzerland, Israel, Russian Federation, Austria, Hungary, Romania, Denmark
Tibotec Pharmaceuticals, Ireland

Completed

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

HIV-1

United States, Canada, France, Belgium, Germany, Spain, Argentina, Chile, Panama, Brazil, Puerto Rico, Thailand, Mexico, Australia
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C223: TMC125 in HIV-1 Infected Subjects

HIV Infection
Indiana University
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study

HIV Infections | Inflammation | Insulin Resistance | Endothelial Function | Lipids

United States
ViiV Healthcare

Completed

Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)

HIV Infections

United States
Pfizer
ViiV Healthcare

Terminated

A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

HIV-1

South Africa, Australia, United Kingdom, Canada, Italy, Poland, Switzerland, Mexico, Brazil
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

HIV

United States, France, Argentina, Chile, Mexico, Costa Rica, Panama, Brazil, Puerto Rico, Thailand
Tibotec Pharmaceuticals, Ireland

Completed

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

HIV-1

United States, Belgium, Germany, Taiwan, Spain, Mexico, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Korea, Republic of, Russian Federation, Puerto Rico, Luxembourg
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients

HIV-1 | Anti-Retroviral Agents
Merck Sharp & Dohme LLC

Completed

Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)

HIV-1 | Central Nervous System
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients

HIV-1 Infection

Spain
Janssen Inc.

Completed

An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients (POISE)

Human Immunodeficiency Virus (HIV)

Canada
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

HIV
Therapeutic Concepts
Abbott; Tibotec, Inc; BluKyne

Completed

A Pilot Study of Kaletra and Intelence Tablets in Naive Subjects (KALYINTE)

HIV Infections

United States
St Stephens Aids Trust

Completed

TMC 125 Blood Levels Study

HIV Infections

United Kingdom

3

Subscribe